Yan Jouroukhin1, Xiaolei Zhu1, Alexey V Shevelkin1, Yuto Hasegawa1, Bagrat Abazyan1, Atsushi Saito1, Jonathan Pevsner2, Atsushi Kamiya3, Mikhail V Pletnikov4. 1. Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland. 2. Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland; Kennedy Krieger Institute, Baltimore, Maryland. 3. Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland. Electronic address: akamiya1@jhmi.edu. 4. Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland; Solomon H. Snyder Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, Maryland. Electronic address: mpletni1@jhu.edu.
Abstract
BACKGROUND: Although several studies have linked adolescent cannabis use to long-term cognitive dysfunction, there are negative reports as well. The fact that not all users develop cognitive impairment suggests a genetic vulnerability to adverse effects of cannabis, which are attributed to action of Δ9-tetrahydrocannabinol (Δ9-THC), a cannabis constituent and partial agonist of brain cannabinoid receptor 1. As both neurons and glial cells express cannabinoid receptor 1, genetic vulnerability could influence Δ9-THC-induced signaling in a cell type-specific manner. METHODS: Here we use an animal model of inducible expression of dominant-negative disrupted in schizophrenia 1 (DN-DISC1) selectively in astrocytes to evaluate the molecular mechanisms, whereby an astrocyte genetic vulnerability could interact with adolescent Δ9-THC exposure to impair recognition memory in adulthood. RESULTS: Selective expression of DN-DISC1 in astrocytes and adolescent treatment with Δ9-THC synergistically affected recognition memory in adult mice. Similar deficits in recognition memory were observed following knockdown of endogenous Disc1 in hippocampal astrocytes in mice treated with Δ9-THC during adolescence. At the molecular level, DN-DISC1 and Δ9-THC synergistically activated the nuclear factor-κB-cyclooxygenase-2 pathway in astrocytes and decreased immunoreactivity of parvalbumin-positive presynaptic inhibitory boutons around pyramidal neurons of the hippocampal CA3 area. The cognitive abnormalities were prevented in DN-DISC1 mice exposed to Δ9-THC by simultaneous adolescent treatment with the cyclooxygenase-2 inhibitor, NS398. CONCLUSIONS: Our data demonstrate that individual vulnerability to cannabis can be exclusively mediated by astrocytes. Results of this work suggest that genetic predisposition within astrocytes can exaggerate Δ9-THC-produced cognitive impairments via convergent inflammatory signaling, suggesting possible targets for preventing adverse effects of cannabis within susceptible individuals.
BACKGROUND: Although several studies have linked adolescent cannabis use to long-term cognitive dysfunction, there are negative reports as well. The fact that not all users develop cognitive impairment suggests a genetic vulnerability to adverse effects of cannabis, which are attributed to action of Δ9-tetrahydrocannabinol (Δ9-THC), a cannabis constituent and partial agonist of brain cannabinoid receptor 1. As both neurons and glial cells express cannabinoid receptor 1, genetic vulnerability could influence Δ9-THC-induced signaling in a cell type-specific manner. METHODS: Here we use an animal model of inducible expression of dominant-negative disrupted in schizophrenia 1 (DN-DISC1) selectively in astrocytes to evaluate the molecular mechanisms, whereby an astrocyte genetic vulnerability could interact with adolescent Δ9-THC exposure to impair recognition memory in adulthood. RESULTS: Selective expression of DN-DISC1 in astrocytes and adolescent treatment with Δ9-THC synergistically affected recognition memory in adult mice. Similar deficits in recognition memory were observed following knockdown of endogenous Disc1 in hippocampal astrocytes in mice treated with Δ9-THC during adolescence. At the molecular level, DN-DISC1 and Δ9-THC synergistically activated the nuclear factor-κB-cyclooxygenase-2 pathway in astrocytes and decreased immunoreactivity of parvalbumin-positive presynaptic inhibitory boutons around pyramidal neurons of the hippocampal CA3 area. The cognitive abnormalities were prevented in DN-DISC1mice exposed to Δ9-THC by simultaneous adolescent treatment with the cyclooxygenase-2 inhibitor, NS398. CONCLUSIONS: Our data demonstrate that individual vulnerability to cannabis can be exclusively mediated by astrocytes. Results of this work suggest that genetic predisposition within astrocytes can exaggerate Δ9-THC-produced cognitive impairments via convergent inflammatory signaling, suggesting possible targets for preventing adverse effects of cannabis within susceptible individuals.
Authors: Analucía A Alegría; Deborah S Hasin; Edward V Nunes; Shang-Min Liu; Carrie Davies; Bridget F Grant; Carlos Blanco Journal: J Clin Psychiatry Date: 2010-09 Impact factor: 4.384
Authors: Patrick D Skosnik; Giri P Krishnan; Deepak C D'Souza; William P Hetrick; Brian F O'Donnell Journal: Neuropsychopharmacology Date: 2014-07-03 Impact factor: 7.853
Authors: Kun Yang; Mari A Kondo; Hanna Jaaro-Peled; Tyler Cash-Padgett; Shin-Ichi Kano; Koko Ishizuka; Jonathan Pevsner; Toshifumi Tomoda; Akira Sawa; Minae Niwa Journal: Schizophr Res Date: 2019-06-13 Impact factor: 4.939
Authors: Jacqueline-Marie N Ferland; Randall J Ellis; Gregory Rompala; Joseph A Landry; James E Callens; Annie Ly; Micah D Frier; Teddy O Uzamere; Yasmin L Hurd Journal: Mol Psychiatry Date: 2022-03-02 Impact factor: 15.992
Authors: Amber S Kleckner; Ian R Kleckner; Charles S Kamen; Mohamedtaki A Tejani; Michelle C Janelsins; Gary R Morrow; Luke J Peppone Journal: Ther Adv Med Oncol Date: 2019-08-01 Impact factor: 8.168
Authors: Alexey V Shevelkin; Chantelle E Terrillion; Yuto Hasegawa; Olga A Mychko; Yan Jouroukhin; Akira Sawa; Atsushi Kamiya; Mikhail V Pletnikov Journal: Hum Mol Genet Date: 2020-10-10 Impact factor: 6.150